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AbstrACt
Introduction People with bipolar disorder require 
long-term treatment but it is estimated that 40% of 
these people do not adhere to prescribed medication 
regimens. Non-adherence increases the risk of relapse, 
hospitalisation and suicide. Some evidence syntheses 
report barriers to mental health treatment adherence but 
rarely delineate between modifiable and non-modifiable 
barriers. They also fail to distinguish between the patients’ 
perspective and that of other stakeholders such as 
clinicians despite of their different understanding and 
priorities about adherence. Facilitators of adherence, which 
are also important for informing adherence intervention 
design, are also lacking from syntheses and few syntheses 
focus on medications for bipolar disorder. This systematic 
review aims to identify modifiable barriers and facilitators 
(determinants) of medication adherence in bipolar disorder. 
We also plan to report determinants of medication 
adherence from perspectives of patients, carers, 
healthcare professionals and other third parties. A unique 
feature of this systematic review in the context of mental 
health is the use of the Theoretical Domains Framework 
(TDF) to organise the literature identified determinants of 
medication adherence.
Methods and analysis The protocol adheres to 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Protocols and ENhancing Transparency in 
REporting the synthesis of Qualitative research (ENTREQ) 
guidelines. This review will include both qualitative and 
quantitative primary studies exploring determinants of 
medication adherence in bipolar disorder. We will search 
the following databases using a preplanned strategy: 
CINAHL, Cochrane Library (CENTRAL), Embase, LiLACS, 
Medline, PsychINFO, PubMed without date restrictions. 
We will report the quality of included studies. We will 
use framework synthesis using the TDF as an a priori 
‘framework’. We will map the literature identified 
modifiable determinants to the domains of TDF.
Ethics and dissemination Ethical approval is not 
required as primary data will not be collected. The results 
will be disseminated through a peer-reviewed publication.
PrOsPErO registration number CRD42018096306.
IntrOduCtIOn
The lifetime prevalence of bipolar disorder 
is estimated at 1.4% of the UK adult popu-
lation.1 Bipolar disorder, featuring mood 
and activity level disturbance, is a recurrent 
disorder and usually requires long-term main-
tenance therapy.1 2 However, it is estimated 
that 40% of people with bipolar disorder 
do not take their medication as prescribed.3 
This non-adherence (generally described as 
taking less than 80% of prescribed doses of 
medication)4 increases the risk of relapse, 
suicide and hospitalisation.5 6 For example, 
the probability of hospitalisation of non-ad-
herent patients with bipolar disorder is at 
least five times higher than that of adherent 
patients.7
strengths and limitations of this study
 ► As the Theoretical Domains Framework (TDF) has 
been mapped to evidence-based behaviour change 
techniques, mapping modifiable determinants of 
medication adherence in bipolar disorder to the TDF 
offer significant utility for intervention development.
 ► This study will provide literature  identified barriers 
and facilitators (determinants) of medication adher-
ence in bipolar disorder from the perspectives of 
patients, carers, healthcare professionals and other 
third parties such as researchers.
 ► Lack of data and quality of reporting may limit our 
ability to present determinants of adherence from 
perspectives of patients, carers, healthcare profes-
sionals and other third parties.
 ► Variation in the terms that is used to describe deter-
minants of adherence may introduce a risk of map-
ping errors through misinterpretation of the reported 
barrier or facilitator.
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Adhering to prescribed medication regimes is a complex 
health behaviour, which requires the patient to obtain the 
prescribed medication, have the physical and cognitive 
ability (practical function), and motivation (perceptual 
function) to take the medication.8 Furthermore, non-ad-
herence may occur at initiation (ie, patient may or may 
not start the treatment), implementation (ie, patient 
may delay, omit or take extra doses during treatment) or 
persistence (ie, patient may discontinue treatment after 
some time) phase.9 There are many reported barriers and 
facilitators (determinants) of medication adherence. For 
this review, a barrier is defined as ‘a circumstance that 
prevents the patients from taking their medication as 
prescribed’, whereas a facilitator is ‘a circumstance that 
makes the process easy or easier’.10 We mention these 
barriers and facilitators as ‘determinants’.
The challenges to successfully address non-adherence 
are to:
1. Accurately identify non-adherent behaviour.
2. Determine individuals’ determinants of medication 
adherence.
3. Select the most appropriate individualised adherence 
intervention(s) underpinned by health psychology 
theory and empirical evidence.11 12
There are various objective (eg, drug plasma levels, pill 
counts and electronic monitoring of medication adher-
ence such as medication event monitoring systems) and 
subjective (eg, self-reported, carer or relative reported, 
clinician reported adherence rating scales) approaches 
to identify patients not adhering to their prescribed 
medication for bipolar disorder.13 However, there are 
no validated tools for comprehensively eliciting from 
patients and/or their carers their individual determi-
nants of adherence to their prescribed medication for 
bipolar disorder. There is also an absence of theory 
and evidence informed guidance for practitioners to 
work with patients in selecting the most effective inter-
ventions for identified determinants of an individual’s 
non-adherent behaviour.
In order to generate such a tool, there is, therefore, a 
need to synthesise the available evidence regarding deter-
minants of medication adherence in patients with bipolar 
disorder.
A recent systematic review (literature search restricted 
to 1990–2015) of adherence to antipsychotic medication 
in bipolar disorder and schizophrenia has provided a 
good overview of the likely barriers experienced by people 
with bipolar disorder.14 However, it failed to explore 
factors that might facilitate adherence and excluded 
studies involving medication other than antipsychotics, 
and therefore did not identify determinants of adherence 
to lithium and other mood stabilisers. This is a signifi-
cant omission as lithium is considered the gold-standard 
first-line treatment for bipolar disorder.1 15 16 The deter-
minants of adherence may be different among patients 
taking lithium relative to other antipsychotics due to a 
variety of factors including regular blood test require-
ments of lithium, dietary restrictions and significant 
interactions with other medications. Thus, a systematic 
review without the date limits of the previous systematic 
review14 is warranted to better represent the mood stabi-
lisers that were the mainstay of treatment in the earlier 
decades and not included in the previous review and to 
identify emerging research.17
The dearth of adherence evidence syntheses in the 
mental health setting underpinned by health psychology 
theory14 18–20 is of concern given its importance for 
informing intervention design and implementation.11 12 
The Theoretical Domains Framework (TDF) is a compre-
hensive framework capturing 33 theories and 84 theoret-
ical constructs related to behaviour change.21 The TDF 
comprises 14 domains, each of which has been coupled 
with evidence-based behaviour change techniques.22 The 
TDF therefore offers an appropriate theory for underpin-
ning an evidence synthesis of determinants of adherence 
as it will enable determinants to be linked to evidence-
based behaviour change techniques. This in turn will 
inform the development of an adherence intervention 
to support practitioners and patients to work together 
in identifying an individual’s key determinants of adher-
ence and select the most appropriate evidence-based 
interventions.
The perspective of patients, carers and healthcare 
professionals often differ in terms of the determinants 
of medication adherence due to differing priorities 
and knowledge of the situation.18 23–26 For example, the 
healthcare professional is generally the expert regarding 
how the medication should be taken while the patient 
and carer are the experts in the patient’s lived experi-
ence of taking or trying to take the prescribed medica-
tion. Furthermore, some determinants such as sex, age 
and ethnicity are not modifiable, and therefore have 
no related specific evidence-based behaviour change 
techniques.
A literature review matching adherence interventions 
to determinants of adherence concluded that adherence 
interventions are often not congruent with the modifiable 
determinants of adherence.27 We will explore the modi-
fiable determinants of medication adherence among 
patients with bipolar disorder from the perspectives of 
the patient, carer, healthcare professional and other third 
parties such as researchers. For the purpose of this system-
atic review, we define modifiable as ‘any determinants 
(barriers or facilitators) of medication adherence that 
can be modified by the patient, carer or the prescriber 
to improve adherence. Modifiable in the context of an 
individual being able to effect the change themselves or 
in partnership with their carer or healthcare team within 
a short timeframe’.
For example, knowledge about the condition/treat-
ment can be changed within days or weeks. In contrast, 
while substance abuse can be changed over an extended 
period, a change is unlikely to be achievable within the 
timeframes acceptable for improving adherence.
This systematic review is a part of the Collaborative 
Medication Adherence in Bipolar disorder (C-MAB) 
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project funded by Health Education England/National 
Institute of Health Research UK. The C-MAB project 
aims to develop a medication adherence tool for people 
with bipolar disorder. The tool is intended to identify 
both non-adherent behaviour and the individual’s deter-
minants of non-adherence. Following the systematic 
review, we will develop the tool in the form of statements 
derived from the literature identified modifiable deter-
minants of adherence. We will then refine the statements 
by conducting focus groups and interviews with patients 
with bipolar disorder and their carers to better under-
stand and prioritise the literature identified modifiable 
determinants. After appropriate refinement, the tool will 
be tested with patients with bipolar disorder.
Aim
To identify modifiable determinants of medication adher-
ence in the treatment of bipolar disorder.
Objectives
 ► To describe the modifiable determinants of medi-
cation adherence from the perspectives of patients, 
carers, healthcare professionals and any other third 
parties.
 ► To map reported modifiable determinants of medica-
tion adherence to the domains of the TDF.
MEthOd
This research protocol is based on ENhancing Transpar-
ency in REporting the synthesis of Qualitative research 
(ENTREQ)28 and Preferred Reporting Items for System-
atic Reviews and Meta-Analyses Protocols (PRISMA-P).29 
The protocol is registered with PROSPERO— www. crd. 
york. ac. uk/ PROSPERO/—international prospective 
register of systematic reviews.
Evidence synthesis
We will use the TDF as an a priori framework for our 
review. We will map the extracted modifiable determi-
nants of adherence from the included studies to the 
domains of the TDF. The deductive approach of this 
framework synthesis method30–33 has the potential to 
restrict the nature of identified determinants. However, 
the comprehensive nature of the TDF should enable 
identification of all determinants relevant to behaviour 
change and any determinants that cannot be mapped to 
a TDF domain will still be extracted and mapped to new 
domains if appropriate.34 A further benefit of mapping 
determinants to the TDF is its linkage to behaviour 
change techniques.17 This approach was successfully 
applied by Allemann and colleagues to match adher-
ence interventions to determinants of patient adher-
ence.27 This early identification of relevant behaviour 
change techniques affords a substantial advantage in 
terms of informing the design of theory and evidence-
based medication adherence interventions for people 
under prescribed medication for bipolar disorder.
Approach to searching, search strategy and data sources
We will employ a preplanned search strategy to seek all 
relevant studies. Our search strategy will consist of three 
parameters: disease (bipolar disorder), treatment (medi-
cation) and outcome (adherence). Following a scoping 
exercise of search terms (on Pubmed, Medline and 
Embase) to define our search strategy, we decided to use 
the MeSH (Medical Subject Heading) terms ‘Treatment 
Adherence and Compliance’, ‘Bipolar Disorder’ and 
‘Psychotropic Drugs’ for our search. We will adapt these 
search terms for the databases that do not permit MeSH 
terms or use different MeSH terms.
We will search the following databases: CINAHL, 
Cochrane Library (CENTRAL), Embase, LiLACS, 
Medline, PsychINFO, Pubmed and the reference list of 
all included studies will be reviewed for further relevant 
studies.
study inclusion criteria
We will include any primary studies; both qualitative 
and quantitative for example, focus groups, interviews 
and surveys; explicitly reporting one or more modifiable 
determinants of medication adherence in the mainte-
nance treatment of bipolar disorders from the perspective 
of patients, carers, healthcare professionals or any other 
third parties. There will be no date restrictions but we will 
include only the studies published in English language. 
We will include studies of patients aged 18 years and above 
with bipolar disorder with or without other comorbidities 
including dual diagnosis, other mental or physical health 
conditions to represent the real-world patient population. 
We will exclude reviews, intervention studies to improve 
adherence, case reports, letters, editorials, commentaries, 
opinion pieces, clinical guidelines or general disease 
management articles and studies not involving humans. 
We will also exclude studies involving short-term treat-
ment of acute agitation or treatment other than medi-
cation such as psychotherapy. Studies where effect of 
individual barriers/facilitators to adherence could not 
be isolated/extracted from composite measures (such as 
adherence rating scale) will be excluded.
study screening methods
We will use computer software Covidence,35 an online 
systematic review program, for screening retrieved 
studies. Screening of studies for inclusion in this review 
will involve three distinct stages:
I. Title Screening: After removal of duplicates using 
the reference manager software Mendeley, the re-
maining studies will be screened for their relevance 
to the review. Definite non-relevant studies will be 
excluded while relevant, or unclear studies, will be 
retained for abstract screening.
II. Abstract Screening: Abstracts of the remaining stud-
ies will be screened by the primary reviewer (AP) 
and second reviewers (CG, DB, FS, GM, JW and 
SS) independently to identify studies that potential-
ly meet the inclusion criteria outlined earlier. Any 
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disagreement between the two reviewers will be re-
solved through further discussion and referral to a 
third reviewer (DB) if there is a failure to achieve 
agreement.
III. Full Article Screening: Full articles will be reviewed 
independently by two reviewers (AP, CG, DB, FS, GM, 
JW and SS) using predefined inclusion/exclusion 
criteria. Any disagreement between two reviewers 
will be resolved through discussion or the involve-
ment of the third reviewer. We will use Cohen’s kap-
pa to report the level of agreement between first and 
second reviewers.
Within published syntheses of qualitative research, 
there is often a lack of transparency about the search 
processes employed, with neither the search strategy nor 
databases detailed.28 For a comprehensive approach, we 
will use the PRISMA flowchart for reporting different 
phases of searching, screening and identifying studies for 
inclusion in the qualitative synthesis as recommended by 
ENTREQ.28
data extraction and mapping
We will use the computer software program Nvivo V.1236 
to extract data and to map the modifiable determinants 
of medication adherence to the domains of the TDF. 
While medication adherence is generally described as 
taking ≥80% doses of prescribed medications, some 
studies report adherence in gradient terms (eg, good, 
moderate, low adherence and non-adherence).4 Yet, in 
some cases (eg, in HIV), adherence means taking ≥95% 
doses of prescribed medications.36 37 Acknowledging 
this wide variation on definition of medication adher-
ence, we will report the definition used for adherence 
in included studies for transparency and comparison 
among studies. Extracted information will include study 
characteristics (eg, title, year of publication, country, 
study design, population, number of participants, defi-
nition and rate of adherence) and modifiable determi-
nants of medication adherence in patients with bipolar 
disorder.
We will map each extracted determinant to one of 
the following domains of the TDF: (1) Knowledge, (2) 
Skills, (3) Social Influences, (4) Memory, Attention and 
Decision Processes, (5) Behavioural Regulation, (6) 
Professional/Social Role and Identity, (7) Beliefs about 
Capabilities, (8) Belief about Consequences, (9) Opti-
mism, (10) Intentions, (11) Goals, (12) Emotion, (13) 
Environmental Context and Resources and (14) Rein-
forcement. We will use constructs within the domains 
and construct definitions of the TDF21 to inform 
mapping decisions. Any determinants that do not 
fit within the existing domains will be organised into 
‘Others’ domain.34
Within Nvivo V.12, we will create four themes in line 
with the aim of this study:
1. Patient  Perspective.
2. Carers Perspective.
3. HealthCare Professional Perspective.
4. Others Perspectives.
Within each theme we will create two subthemes 
(Barriers and Facilitators), and within each of these 
subthemes we will create 15 domains (14 TDF domains 
plus ‘Others’).
Two reviewers will pilot data extraction and coding 
of determinants of adherence to the domains of TDF 
from four studies. For example, if the following text 
was extracted from a study ‘Forgetting to take medica-
tion or being careless at times about taking medication 
was reported to be experienced by x participants’, this 
would be coded to the TDF domain ‘Memory, attention 
and decision process’. The reviewers will then compare 
and discuss their coding to generate consensus in inter-
pretation of literature identified determinants. After 
piloting, all data will be extracted by one reviewer 
and independently checked by second reviewer for 
completeness.
All extracted determinants will be independently 
mapped onto the 14 domains of the TDF or ‘Others’ 
category by two reviewers. The two reviewers will meet 
and discuss their mapping regularly. Any disagreement in 
mapping will be resolved through discussion between the 
two reviewers and referral to a third reviewer as adjudi-
cator if the two reviewers fail to agree. We will use Cohen’s 
kappa to report agreement between the first and second 
reviewers as we are dealing with nominal data, that is, 
agreement and not with the domain to which a determi-
nant is mapped onto the TDF.
Quality assessment
No studies will be excluded based on quality as our 
aim is to identify determinants of medication adher-
ence as comprehensively as possible. However, we will 
undertake a quality assessment for the purposes of char-
acterising included studies. There is neither gold-stan-
dard tool for any study design nor is there any widely 
accepted generic quality assessment tool that functions 
across multiple study types.38 We will use bespoke Crit-
ical Appraisal Skills Programme qualitative (CASP),39 
Critical appraisal of survey40 and Cochrane risk of bias 
tool41 to critically appraise qualitative studies, surveys 
and trials, respectively. These tools meet the require-
ments of the study and provide key quality criteria such 
as validity, reliability and objectivity.42 Quality assess-
ment will be carried out by two independent reviewers. 
Any disagreement between reviewers will be resolved 
through discussion and, if necessary, referral to a third 
reviewer for arbitration.
Patient and public involvement
This systematic review is a part of the C-MAB project 
that include three patients and a carer as research advi-
sory board members. Patient and public involvement 
(PPI) has influenced the study design with two notable 
recommendations: inclusion of the carer’s perspective on 
medication adherence and differentiating between modi-
fiable and non-modifiable determinants of medication 
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adherence. Two PPI representatives (CG and RG) are 
listed as authors.
EthICs And dIssEMInAtIOn
Ethical approval is not required as primary data will not 
be collected. The results will be disseminated through a 
peer-reviewed publication.
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